Ellegaard et al. demonstrated in a cohort of 109 RA patients that baseline PDUS predicted persistence of anti-TNF-alpha therapy whereas conventional clinical measures at baseline did not [29]. The gene discussed is TNF; the disease is rheumatoid arthritis.